Format

Send to

Choose Destination
Br J Haematol. 2019 Mar 7. doi: 10.1111/bjh.15840. [Epub ahead of print]

Comments on pre-fibrotic myelofibrosis and how should it be managed.

Author information

1
FROM Research Foundation, Papa Giovanni XXIII Hospital, Bergamo, Italy.
2
Institute of Pathology, University of Cologne, Cologne, Germany.
3
Department of Internal Medicine I, Division of Haematology and Haemostaseology, Medical University of Vienna, Vienna, Austria.
4
Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY, USA.
5
Department of Experimental and Clinical Medicine, Centre of Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliera Universitaria Careggi, University of Florence, Florence, Italy.
6
Division of Pathology, Department of Pathophysiology and Transplantation, University of Milan, and IRCCS Ca' Granda-Maggiore Policlinico Hospital Foundation, Milan, Italy.
7
Institute of Pathology, Medical University of Graz, Graz, Austria.
8
Mayo Clinic, Rochester, MN, USA.

KEYWORDS:

bone marrow morphology; clinical data; essential thrombocythaemia; pre-fibrotic myelofibrosis; prognosis

PMID:
30847907
DOI:
10.1111/bjh.15840

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center